Lung Cancer (ALK): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a A 70-year-old male non-smoker was in his normal state of health until approximately 2 months ago when he developed progressively worsening low back pain. A lumbar spine MRI displayed multiple lesions and a biopsy of the lumbar spine confirmed adenocarcinoma, most likely, lung primary. Immunostaining showed that the tumor was diffusely positive for keratins (AE1/3, K903, and CK7), TTF-1 and napsin, and negative for CK20, PSA, PAP, CDX-2, CD10, ERG, and CD45. He was started on crizotinib and showed a partial response.

Learning Objectives

  • Identify the issues associated with molecular testing for non-small cell lung cancer
  • Discuss the optimal management of ALK positive lung cancer
  • Describe the mechanisms of resistance to ALK inhibitors

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits 
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on April 25, 2020. Participants must complete all necessary course components by this date to receive credit.